CoChat

Safety and Immunogenicity of Hepatitis A Vaccine in Human Immunodeficiency Virus–Infected Patients: A Double‐Blind, Randomized, Placebo‐Controlled Trial

Open access
Kemper, Carol A., Haubrich, Richard, Frank, Ian, Dubin, Gary, Buscarino, Charles, McCutchan, J. Allen, Deresinski, Stanley C., California Collaborative Treatment Group · 2003 · The Journal of Infectious Diseases
Cited by 117

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

The safety and immunogenicity of inactivated hepatitis A (HepA) vaccine was assessed in 133 hepatitis A virus-seronegative, human immunodeficiency virus (HIV)-infected adults. Patients were randomly assigned to receive, in a blinded fashion, either 2 doses of vaccine (1440 enzyme-linked immunosorbent assay units) or placebo 6 months apart. Seroconversion at month 9 was observed in 68% of those with CD4 cell counts >/=200 cells/mm(3) but in only 9% of those with lower CD4 cell counts (P=.004). HepA vaccine was well tolerated and had no effect on the course of HIV infection or plasma HIV RNA load.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1086/374562

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • Clinical experience with an inactivated hepatitis A vaccine.

    Clemens, R., Safary, A., Hepburn, A., Roche, C., Stanbury, W. J., & Andre, F. E. (1995) · Journal of Infectious Diseases · doi:10.1093/infdis/171.supplement_1.s44 · Cited by 223 · cited 1×

    “HAVRIX (GlaxoSmithKline Beecham Biologicals), one of the inactivated HepA vaccines currently licensed in the United States, is highly immunogenic in non– HIV-infected adults, resulting in seroconversion in up to 90%– 94% and 100% of persons after the first and second doses, respectively, of vaccine (1440 ELISA units […”
    Background

Show all 1 references

Cited by

See all 117

Metadata

Authors
Kemper, C. A., Haubrich, R., Frank, I., Dubin, G., Buscarino, C., McCutchan, J. A., Deresinski, S. C., & California Collaborative Treatment Group
Venue
The Journal of Infectious Diseases
Published
2003-04-15
Volume
187
Issue
8
Pages
1327-1331
ISSN
  • 0022-1899 (ISSN-L)
  • 1537-6613
OpenAlex
W2103917884
Cited by
117
References
1
FWCI
5.91
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety and Immunogenicity of Hepatitis A Vaccine in Human Immunodeficiency Virus–Infected Patients: A Double‐Blind, Randomized, Placebo‐Controlled Trial. https://app.cochat.ai/papers/10.1086/374562
The paper
Kemper, C. A., Haubrich, R., Frank, I., Dubin, G., Buscarino, C., McCutchan, J. A., Deresinski, S. C., & California Collaborative Treatment Group. (2003). Safety and Immunogenicity of Hepatitis A Vaccine in Human Immunodeficiency Virus–Infected Patients: A Double‐Blind, Randomized, Placebo‐Controlled Trial. The Journal of Infectious Diseases. https://doi.org/10.1086/374562

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.